Both the atai Life Sciences IPO and a MindMed uplisting to the NASDAQ are highly anticipated events. They could occur within weeks -- or even days -- of each other.
Exploring the companies and themes that make up this emerging and exciting new sector
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Mydecine announces several steps in its drug R&D, including four new novel drug candidates.
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai acquires a majority stake in Delaware-based Psyber, Inc., which has a strong focus on digital therapeutics.
Microdosing psychedelic drugs associated with increases in conscientiousness and reductions in neuroticism
Microdosing has become something of a wellness trend in recent years, gathering traction in Australia and overseas.
Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement
Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Cashed-Up Psychedelic Stocks Well Prepared For Adverse Market Conditions
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
Northampton City Council seeks to decriminalize psychedelic drugs, urge police make possession low enforcement priority
Efforts are underway to make pursuing criminal charges for possession of psychedelics less of a priority in one Western Massachusetts community.
MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS
MindMed files a "Base Shelf Prospectus" with the SEC.
MINDCURE (CSE: MCUR | OTC: MCURF) Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281
Why Dollar-Cost Averaging Makes Sense For Psychedelic Stocks
Psychedelic stocks have been battered by general market headwinds in recent weeks. Uncertainty could persist. How do investors allocate capital?
Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe
Cybin announces senior management changes as it moves into the next stage of its evolution.
MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform
MindMed announces its year-end results for 2020, cash-on-hand at US$161 million, including a total cash burn for 2020 of US$24.2 million.